Literature DB >> 23459994

Seizures during the management of high-grade gliomas: clinical relevance to disease progression.

Young-Hoon Kim1, Chul-Kee Park, Tae Min Kim, Seung Hong Choi, Yu Jung Kim, Byung Se Choi, Jung Ho Han, Se-Hoon Lee, Chae-Yong Kim, In Ah Kim, Dae Seog Heo, Il Han Kim, Dong Gyu Kim, Hee-Won Jung.   

Abstract

This study was performed to evaluate the incidence of seizures with its implications on disease progression and the diagnostic value of post-ictal magnetic resonance images (MRI) during the management of high-grade gliomas (HGGs). A total of 406 consecutive patients with newly diagnosed HGGs were retrospectively reviewed. The incidence of seizures during the management was investigated. In patients who experienced a seizure, the causality between seizures and disease progression was assessed by pre-ictal, post-ictal (<1 month), and follow-up (<3 months) MRI. After a median follow-up of 17.4 months (range 0.1-88.3), seizures developed in 127 patients (31 %). Of the 127 patients, radiological progression at the post-ictal MRI was found in 83 patients (65 %) and the follow-up MRI confirmed progression in 79 patients (62 %). Four other patients (3 %) were shown to be progression-free. Among those without radiological progression at the post-ictal MRI, the follow-up MRI confirmed progression-free in 31 patients (24 %); however, 13 patients (10 %) revealed eventual progression. In the patients with a seizure, absence of preoperative seizures (p = 0.003), <95 % tumor resection (p = 0.001), and pre-ictal Karnofsky Performance Scale score ≤ 70 (p = 0.025) were significantly associated with disease progression. During the management of HGG, 31 % of patients experienced seizures; of these patients, 72 % harbored progressive disease. The post-ictal MRI is useful for detecting disease progression; however, there are pitfalls. Clinical settings should be considered together for diagnosing disease progression in patients with seizures.

Entities:  

Mesh:

Year:  2013        PMID: 23459994     DOI: 10.1007/s11060-013-1094-6

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  25 in total

Review 1.  Brain tumors.

Authors:  L M DeAngelis
Journal:  N Engl J Med       Date:  2001-01-11       Impact factor: 91.245

2.  Response criteria for phase II studies of supratentorial malignant glioma.

Authors:  D R Macdonald; T L Cascino; S C Schold; J G Cairncross
Journal:  J Clin Oncol       Date:  1990-07       Impact factor: 44.544

3.  Epileptic seizures in supratentorial gliomas.

Authors:  P N Tandon; A K Mahapatra; A Khosla
Journal:  Neurol India       Date:  2001-03       Impact factor: 2.117

4.  SMART: stroke-like migraine attacks after radiation therapy.

Authors:  D F Black; J D Bartleson; M L Bell; D H Lachance
Journal:  Cephalalgia       Date:  2006-09       Impact factor: 6.292

5.  [Multimodal treatment of glioblastoma multiforme: results of 86 consecutive patients diagnosed in period 2003-2009].

Authors:  R Lakomý; P Fadrus; P Slampa; T Svoboda; L Kren; E Lzicarová; R Belanová; I Siková; A Poprach; M Schneiderová; M Procházková; J Sána; O Slabý; M Smrcka; R Vyzula; M Svoboda
Journal:  Klin Onkol       Date:  2011

6.  Temozolomide during and after radiation therapy for WHO grade III gliomas: preliminary report of a prospective multicenter study.

Authors:  Young-Hoon Kim; Chul-Kee Park; Won Ho Cho; In Ah Kim; Seyoung Moon; Gheeyoung Choe; Sung-Hye Park; Il Han Kim; Dong Gyu Kim; Hee-Won Jung; Min Mi Lee; So Hyun Bae; Seung Heon Cha; Chae-Yong Kim
Journal:  J Neurooncol       Date:  2010-09-24       Impact factor: 4.130

7.  Conditional probability of survival in patients with newly diagnosed glioblastoma.

Authors:  Mei-Yin C Polley; Kathleen R Lamborn; Susan M Chang; Nicholas Butowski; Jennifer L Clarke; Michael Prados
Journal:  J Clin Oncol       Date:  2011-10-03       Impact factor: 44.544

8.  Preoperative and postoperative seizures in patients with astrocytic tumours: analysis of incidence and influencing factors.

Authors:  S L Hwang; A S Lieu; T H Kuo; C L Lin; C Z Chang; T Y Huang; S L Howng
Journal:  J Clin Neurosci       Date:  2001-09       Impact factor: 1.961

9.  MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.

Authors:  Alba A Brandes; Enrico Franceschi; Alicia Tosoni; Valeria Blatt; Annalisa Pession; Giovanni Tallini; Roberta Bertorelle; Stefania Bartolini; Fabio Calbucci; Alvaro Andreoli; Giampiero Frezza; Marco Leonardi; Federica Spagnolli; Mario Ermani
Journal:  J Clin Oncol       Date:  2008-05-01       Impact factor: 44.544

10.  Efficacy of anti-epileptic drugs in patients with gliomas and seizures.

Authors:  Mèlanie S M van Breemen; R M Rijsman; M J B Taphoorn; R Walchenbach; H Zwinkels; Charles J Vecht
Journal:  J Neurol       Date:  2009-05-12       Impact factor: 4.849

View more
  9 in total

1.  Health-related quality of life in patients with high-grade gliomas: a quantitative longitudinal study.

Authors:  K Piil; J Jakobsen; K B Christensen; M Juhler; M Jarden
Journal:  J Neurooncol       Date:  2015-05-31       Impact factor: 4.130

2.  Natural course and prognosis of anaplastic gangliogliomas: a multicenter retrospective study of 43 cases from the French Brain Tumor Database.

Authors:  Louis-Marie Terrier; Luc Bauchet; Valérie Rigau; Aymeric Amelot; Sonia Zouaoui; Isabelle Filipiak; Agnès Caille; Fabien Almairac; Marie-Hélène Aubriot-Lorton; Anne-Marie Bergemer-Fouquet; Eric Bord; Philippe Cornu; Alain Czorny; Phong Dam Hieu; Bertrand Debono; Marie-Bernadette Delisle; Evelyne Emery; Walid Farah; Guillaume Gauchotte; Catherine Godfraind; Jacques Guyotat; Bernard Irthum; Kevin Janot; Pierre-Jean Le Reste; Dominique Liguoro; Hugues Loiseau; Guillaume Lot; Vincent Lubrano; Emmanuel Mandonnet; Philippe Menei; Philippe Metellus; Serge Milin; Bertrand Muckenstrum; Pierre-Hugues Roche; Audrey Rousseau; Emmanuelle Uro-Coste; Anne Vital; Jimmy Voirin; Michel Wager; Marc Zanello; Patrick François; Stéphane Velut; Pascale Varlet; Dominique Figarella-Branger; Johan Pallud; Ilyess Zemmoura
Journal:  Neuro Oncol       Date:  2017-05-01       Impact factor: 12.300

3.  Deficiency of very large G-protein-coupled receptor-1 is a risk factor of tumor-related epilepsy: a whole transcriptome sequencing analysis.

Authors:  Yinyan Wang; Xing Fan; Wei Zhang; Chuanbao Zhang; Jiangfei Wang; Tao Jiang; Lei Wang
Journal:  J Neurooncol       Date:  2014-12-16       Impact factor: 4.130

4.  Postoperative epilepsy and survival in glioma patients: a nationwide population-based cohort study from 2009 to 2018.

Authors:  Mirketa Marku; Birthe Krogh Rasmussen; Federica Belmonte; Elisabeth Anne Wreford Andersen; Christoffer Johansen; Pernille Envold Bidstrup
Journal:  J Neurooncol       Date:  2022-01-28       Impact factor: 4.130

5.  Integrative analysis of expression profile indicates the ECM receptor and LTP dysfunction in the glioma-related epilepsy.

Authors:  Zhi-Bin Wang; Jian Qu; Pan Xie; Zhi-Quan Yang; Chen-Xue Mao; Ying Zhang; Zheng-Wen He; Zhuan-Yi Yang; Xiao-Yuan Mao; Zhao-Qian Liu
Journal:  BMC Genomics       Date:  2022-06-08       Impact factor: 4.547

6.  What is New in the Management of Epilepsy in Gliomas?

Authors:  Roberta Rudà; Riccardo Soffietti
Journal:  Curr Treat Options Neurol       Date:  2015-06       Impact factor: 3.598

7.  Expression of RINT1 predicts seizure occurrence and outcomes in patients with low-grade gliomas.

Authors:  Xing Fan; Yin-yan Wang; Chuan-bao Zhang; Gan You; Ming-yang Li; Lei Wang; Tao Jiang
Journal:  J Cancer Res Clin Oncol       Date:  2014-10-11       Impact factor: 4.553

8.  Glutamate weighted imaging contrast in gliomas with 7 Tesla magnetic resonance imaging.

Authors:  Andrew Neal; Bradford A Moffat; Joel M Stein; Ravi Prakash Reddy Nanga; Patricia Desmond; Russell T Shinohara; Hari Hariharan; Rebecca Glarin; Katharine Drummond; Andrew Morokoff; Patrick Kwan; Ravinder Reddy; Terence J O'Brien; Kathryn A Davis
Journal:  Neuroimage Clin       Date:  2019-01-29       Impact factor: 4.881

Review 9.  Controlled rehabilitative and supportive care intervention trials in patients with high-grade gliomas and their caregivers: a systematic review.

Authors:  K Piil; M Juhler; J Jakobsen; M Jarden
Journal:  BMJ Support Palliat Care       Date:  2014-06-02       Impact factor: 3.568

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.